PHGE Insider Trading
Insider Ownership Percentage: 3.01%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $9,249.20
BiomX Share Price & Price History
Current Price: $0.59
Price Change: ▼ Price Decrease of -0.153 (-20.70%)
As of 03/18/2025 04:49 PM ET
BiomX Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
5/15/2024 | Israel Biofund Gp Limi Orbimed | Major Shareholder | Sell | 2,434 | $3.80 | $9,249.20 | 1,377,365 | |
5/22/2023 | Assaf Oron | Insider | Buy | 319 | $2.70 | $861.30 | 1,091 | |
2/27/2023 | Israel Biofund Gp Limi Orbimed | Major Shareholder | Buy | 34,800 | $2.40 | $83,520.00 | 316,148 | |
11/4/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 150 | $3.80 | $570.00 | 299,702 | |
11/2/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 241 | $3.60 | $867.60 | 300,052 | |
10/31/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 330 | $3.70 | $1,221.00 | 300,424 | |
10/28/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 152 | $3.60 | $547.20 | 300,754 | |
10/26/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,250 | $3.50 | $4,375.00 | 301,057 | |
10/24/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 590 | $3.50 | $2,065.00 | 302,614 | |
10/21/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 540 | $3.70 | $1,998.00 | 303,204 | |
10/19/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 450 | $3.70 | $1,665.00 | 304,408 | |
10/17/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 809 | $3.40 | $2,750.60 | 306,388 | |
10/14/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 342 | $3.30 | $1,128.60 | 307,198 | |
10/12/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 970 | $3.30 | $3,201.00 | 308,671 | |
10/10/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,004 | $3.30 | $3,313.20 | 310,240 | |
10/7/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 2,470 | $3.60 | $8,892.00 | 311,244 | |
10/5/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 4,678 | $4.30 | $20,115.40 | 316,225 | |
10/3/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,502 | $3.30 | $4,956.60 | 322,823 | |
9/30/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 866 | $3.60 | $3,117.60 | 324,325 | |
9/28/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,564 | $3.30 | $5,161.20 | 325,522 | |
9/26/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,752 | $3.50 | $6,132.00 | 327,573 | |
9/23/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 530 | $3.70 | $1,961.00 | 329,326 | |
9/21/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 557 | $4.30 | $2,395.10 | 331,595 | |
9/19/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,387 | $4.80 | $6,657.60 | 333,215 | |
9/16/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 320 | $5.10 | $1,632.00 | 334,602 | |
9/14/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 230 | $5.20 | $1,196.00 | 335,312 | |
9/12/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 170 | $5.40 | $918.00 | 335,762 | |
9/8/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 459 | $5.20 | $2,386.80 | 337,254 | |
9/6/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 640 | $5.50 | $3,520.00 | 338,598 | |
9/2/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 200 | $5.50 | $1,100.00 | 339,238 | |
8/31/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 454 | $5.50 | $2,497.00 | 340,268 | |
8/29/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,153 | $5.70 | $6,572.10 | 342,071 | |
8/26/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 6,062 | $6.20 | $37,584.40 | 343,224 | |
8/24/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 866 | $6.50 | $5,629.00 | 351,982 | |
8/22/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 500 | $6.60 | $3,300.00 | 353,438 | |
8/19/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,460 | $6.40 | $9,344.00 | 353,938 | |
8/17/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 2,133 | $6.90 | $14,717.70 | 356,174 | |
8/15/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 720 | $7.50 | $5,400.00 | 359,164 | |
8/12/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,140 | $7.30 | $8,322.00 | 359,884 | |
8/10/2022 | Chidozie Ugwumba | Major Shareholder | Sell | 1,776 | $7.40 | $13,142.40 | 362,007 | |
BiomX Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
2/17/2025 | Alyeska Investment Group L.P. | 865,400 | $0.63M | 0.0% | N/A | 4.761% |  |
2/17/2025 | Allostery Investments LP | 643,833 | $0.47M | 0.5% | N/A | 3.542% |  |
2/14/2025 | Heights Capital Management Inc. | 258,492 | $0.19M | 0.1% | -56.1% | 1.422% |  |
2/14/2025 | Johnson & Johnson | 96,866 | $71K | 0.0% | -49.6% | 0.533% |  |
2/12/2025 | JPMorgan Chase & Co. | 429,990 | $0.31M | 0.0% | N/A | 2.366% |  |
11/19/2024 | Barclays PLC | 25,000 | $26K | 0.0% | -90.0% | 0.138% |  |
11/15/2024 | Barclays PLC | 25,000 | $26K | 0.0% | -90.0% | 0.140% |  |
11/15/2024 | Ikarian Capital LLC | 893,000 | $0.91M | 0.1% | N/A | 4.990% |  |
11/14/2024 | Johnson & Johnson | 192,321 | $0.20M | 0.0% | -90.0% | 1.075% |  |
11/7/2024 | 8VC GP I LLC | 108,621 | $0.11M | 0.2% | -90.0% | 0.607% |  |
5/17/2024 | Ikarian Capital LLC | 10,817,327 | $4.87M | 0.5% | N/A | 19.590% |  |
5/10/2024 | Johnson & Johnson | 1,923,201 | $0.87M | 0.0% | -9.9% | 3.483% |  |
11/3/2022 | Royce & Associates LP | 158,655 | $54K | 0.0% | -51.7% | 0.529% |  |
5/5/2022 | Royce & Associates LP | 320,655 | $0.62M | 0.0% | +200.5% | 1.077% |  |
2/7/2022 | Royce & Associates LP | 106,696 | $0.17M | 0.0% | -52.7% | 0.373% |  |
11/12/2021 | Johnson & Johnson | 2,133,402 | $6.53M | 0.6% | N/A | 7.568% |  |
10/26/2021 | Taylor Wealth Management Partners | 40,098 | $91K | 0.0% | -44.3% | 0.142% |  |
8/17/2021 | Millennium Management LLC | 427,702 | $2.34M | 0.0% | -5.9% | 1.758% |  |
8/17/2021 | Bridgeway Capital Management LLC | 104,000 | $0.57M | 0.0% | -15.4% | 0.427% |  |
5/18/2021 | Millennium Management LLC | 454,377 | $3.24M | 0.0% | -1.2% | 1.954% |  |
5/18/2021 | Jane Street Group LLC | 25,365 | $0.18M | 0.0% | N/A | 0.109% |  |
5/13/2021 | Renaissance Technologies LLC | 36,200 | $0.26M | 0.0% | N/A | 0.156% |  |
5/10/2021 | Royce & Associates LP | 359,000 | $2.56M | 0.0% | N/A | 1.544% |  |
Data available starting January 2016
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Read More on BiomX
Volume
53,300 shs
Average Volume
62,228 shs
Market Capitalization
$10.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.38
Who are the company insiders with the largest holdings of BiomX?
Who are the major institutional investors of BiomX?
Which institutional investors are selling BiomX stock?
During the last quarter, PHGE stock was sold by these institutional investors:
- Heights Capital Management Inc.
- Johnson & Johnson
Which institutional investors are buying BiomX stock?
In the previous quarter, PHGE stock was purchased by institutional investors including:
- Alyeska Investment Group L.P.
- Allostery Investments LP
- JPMorgan Chase & Co.